| Product Code: ETC9966983 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Glaucoma Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Glaucoma Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Glaucoma Market - Industry Life Cycle |
3.4 United States (US) Glaucoma Market - Porter's Five Forces |
3.5 United States (US) Glaucoma Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United States (US) Glaucoma Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 United States (US) Glaucoma Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United States (US) Glaucoma Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 United States (US) Glaucoma Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Glaucoma Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of glaucoma in the United States |
4.2.2 Aging population leading to higher demand for glaucoma treatment |
4.2.3 Technological advancements in glaucoma diagnosis and treatment |
4.2.4 Growing awareness about eye health and regular screenings |
4.2.5 Favorable reimbursement policies for glaucoma treatments |
4.3 Market Restraints |
4.3.1 High cost of glaucoma medications and surgical procedures |
4.3.2 Limited access to specialized eye care services in certain regions |
4.3.3 Side effects associated with some glaucoma treatments |
4.3.4 Lack of patient compliance with treatment regimens |
4.3.5 Competition from alternative therapies and treatments |
5 United States (US) Glaucoma Market Trends |
6 United States (US) Glaucoma Market, By Types |
6.1 United States (US) Glaucoma Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Glaucoma Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United States (US) Glaucoma Market Revenues & Volume, By Closed Angle Glaucoma (CAG), 2021- 2031F |
6.1.4 United States (US) Glaucoma Market Revenues & Volume, By Open Angle Glaucoma (OAG), 2021- 2031F |
6.1.5 United States (US) Glaucoma Market Revenues & Volume, By Secondary Glaucoma, 2021- 2031F |
6.1.6 United States (US) Glaucoma Market Revenues & Volume, By Congenital Glaucoma, 2021- 2031F |
6.1.7 United States (US) Glaucoma Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Glaucoma Market, By Drug Class |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Glaucoma Market Revenues & Volume, By Beta Blockers, 2021- 2031F |
6.2.3 United States (US) Glaucoma Market Revenues & Volume, By Prostaglandins, 2021- 2031F |
6.2.4 United States (US) Glaucoma Market Revenues & Volume, By Alpha Adrenergic Agonist, 2021- 2031F |
6.2.5 United States (US) Glaucoma Market Revenues & Volume, By Carbonic Anhydrase Inhibitors, 2021- 2031F |
6.2.6 United States (US) Glaucoma Market Revenues & Volume, By Combination Drugs, 2021- 2031F |
6.2.7 United States (US) Glaucoma Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Glaucoma Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Glaucoma Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United States (US) Glaucoma Market Revenues & Volume, By Injections, 2021- 2031F |
6.3.4 United States (US) Glaucoma Market Revenues & Volume, By Intravitreal, 2021- 2031F |
6.3.5 United States (US) Glaucoma Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Glaucoma Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Glaucoma Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Glaucoma Market Revenues & Volume, By Speciality Centres, 2021- 2031F |
6.4.4 United States (US) Glaucoma Market Revenues & Volume, By Others, 2021- 2031F |
6.5 United States (US) Glaucoma Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 United States (US) Glaucoma Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 United States (US) Glaucoma Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 United States (US) Glaucoma Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 United States (US) Glaucoma Market Import-Export Trade Statistics |
7.1 United States (US) Glaucoma Market Export to Major Countries |
7.2 United States (US) Glaucoma Market Imports from Major Countries |
8 United States (US) Glaucoma Market Key Performance Indicators |
8.1 Average age of glaucoma diagnosis in the US population |
8.2 Percentage of population undergoing regular eye screenings for glaucoma |
8.3 Adoption rate of advanced glaucoma diagnostic technologies |
8.4 Number of glaucoma specialists per capita in different regions of the US |
8.5 Patient satisfaction with glaucoma treatment options and services |
9 United States (US) Glaucoma Market - Opportunity Assessment |
9.1 United States (US) Glaucoma Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United States (US) Glaucoma Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.3 United States (US) Glaucoma Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United States (US) Glaucoma Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 United States (US) Glaucoma Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Glaucoma Market - Competitive Landscape |
10.1 United States (US) Glaucoma Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Glaucoma Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |